专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2003070747A3 INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS 审中-公开
公开(公告)号：WO2003070747A3
公开(公告)日：2003-08-28
申请号：PCT/US2002/030312
申请日：2002-09-24
申请人： NOVO NORDISK A/S , DGI BIOTECHNOLOGIES , PILLUTLA, Renuka , BRISSETTE, Renee , BLUME, Arthur, J. , SCHÄFFER, Lauge , BRANDT, Jakob , GOLDSTEIN, Neil, I. , SPETZLER, Jane , OSTERGAARD, Soren
发明人： PILLUTLA, Renuka , BRISSETTE, Renee , BLUME, Arthur, J. , SCHÄFFER, Lauge , BRANDT, Jakob , GOLDSTEIN, Neil, I. , SPETZLER, Jane , OSTERGAARD, Soren
IPC分类号： A61K38/28
摘要： Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.

12. 发明申请

WO2011080103A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES 审中-公开
标题翻译：双酚A-GLP-1衍生物
公开(公告)号：WO2011080103A1
公开(公告)日：2011-07-07
申请号：PCT/EP2010/069932
申请日：2010-12-16
申请人： NOVO NORDISK A/S , GARIBAY, Patrick, William , SPETZLER, Jane , KODRA, János, Tibor , LINDEROTH, Lars , LAU, Jesper , SAUERBERG, Per
发明人： GARIBAY, Patrick, William , SPETZLER, Jane , KODRA, János, Tibor , LINDEROTH, Lars , LAU, Jesper , SAUERBERG, Per
IPC分类号： C07K14/605 , A61K47/48
CPC分类号： C07K14/65 , A61K38/00 , A61K47/542 , A61K47/60 , C07K14/605 , G01N2333/605
摘要： The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1 (7-37), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37), wherein the first K residue is designated K 37 , and the second K residue is designated K 26 , which derivative comprises two albumin binding moieties attached to K 26 and K 37 , respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: Chem. 1 : HOOC-(CH 2 ) X -CO-* Chem. 2: HOOC-C 6 H 4 -O-(CH 2 ) y -CO-* Chem. 3: R 1 -C 6 H 4 -(CH 2 ) Z -CO-* Chem. 4: HOOC-C 4 SH 2 -(CH 2 ) W -CO-* in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1 -5, R 1 is a group having a molar mass not higher than 150 Da, and w is an integer in the range of 6-18; with the proviso that when the protracting moiety is Chem. 1, the albumin binding moiety further comprises a linker of formula Chem. 5: *-NH-(CH 2 ) 2 -(O-(CH 2 ) 2 ) k -O-(CH 2 ) n -CO-*, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.
摘要翻译：本发明涉及GLP-1类似物的衍生物，其类似物包含在对应于GLP-1（7-37）（SEQ ID NO：1）的第37位的位置处的第一个K残基，相对于GLP-1（7-37）的位置26的位置和与GLP-1（7-37）相比最多10个氨基酸修饰，其中第一个K残基指定为K37，第二个K残基是命名为K26，该衍生物分别包含与K26和K37连接的两个白蛋白结合部分，其中白蛋白结合部分包含选自下列的伸长部分： 1：HOOC-（CH2）X-CO- * Chem。 2：HOOC-C6H4-O-（CH2）y-CO- * 3：R1-C6H4-（CH2）Z-CO- * Chem。 4：HOOC-C4SH2-（CH2）W-CO- *，其中x是6-18的整数，y是3-17的整数，z是1〜 5，R1是摩尔质量不高于150Da的基团，w是6-18的整数; 条件是当伸长部分是Chem。如图1所示，白蛋白结合部分还包含式Chem的接头。 5：* -NH-（CH2）2-（O-（CH2）2）kO-（CH2）n-CO- *，其中k是1-5的整数，n是范围1-5; 或其药学上可接受的盐，酰胺或酯。本发明还涉及其药物用途，例如用于治疗和/或预防所有形式的糖尿病和相关疾病，以及相应的新型肽和侧链中间体。该衍生物适合口服给药。

13. 发明申请

WO2008087186A2 NOVEL PEPTIDES FOR USE IN THE TREATMENT OF OBESITY 审中-公开
标题翻译：用于治疗肥胖症的新型药物
公开(公告)号：WO2008087186A2
公开(公告)日：2008-07-24
申请号：PCT/EP2008/050512
申请日：2008-01-17
申请人： NOVO NORDISK A/S , SENSFUSS, Ulrich , CONDE FRIEBOES, Kilian Waldemar , SPETZLER, Jane
发明人： SENSFUSS, Ulrich , CONDE FRIEBOES, Kilian Waldemar , SPETZLER, Jane
IPC分类号： C07K14/68 , A61K38/34
CPC分类号： C07K14/68
摘要： The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to meth- ods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the in- vention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
摘要翻译：本发明涉及在治疗中有效调节一种或多种黑皮质素受体类型，化合物在治疗中的用途的新型肽化合物，包括向有需要的患者施用化合物，以及使用的药物制造中的化合物。本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面特别有意义。

14. 发明申请

WO2007009894A2 NOVEL PEPTIDES FOR USE IN THE TREATMENT OF OBESITY 审中-公开
标题翻译：用于治疗肥胖症的新型药物
公开(公告)号：WO2007009894A2
公开(公告)日：2007-01-25
申请号：PCT/EP2006/064027
申请日：2006-07-07
申请人： NOVO NORDISK A/S , SENSFUSS, Ulrich , CHRISTENSEN, Leif , SPETZLER, Jane , FRIEBOES, Kilian Waldemar Conde , THØGERSEN, Henning
发明人： SENSFUSS, Ulrich , CHRISTENSEN, Leif , SPETZLER, Jane , FRIEBOES, Kilian Waldemar Conde , THØGERSEN, Henning
IPC分类号： A61K47/48 , C07K7/06 , C07K7/08
CPC分类号： C07K14/685 , A61K47/542 , A61K47/545
摘要： The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
摘要翻译：本发明涉及有效调节一种或多种黑皮质素受体类型的新型肽化合物，治疗中化合物的用途，包括向有需要的患者施用化合物的治疗方法，以及使用药物制造中的化合物。本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面特别有意义。

15. 发明申请

WO2009030738A1 GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE 审中-公开
标题翻译： GLUCAGON-LIKE PEPTIDE-1衍生物及其药物用途
公开(公告)号：WO2009030738A1
公开(公告)日：2009-03-12
申请号：PCT/EP2008/061755
申请日：2008-09-05
申请人： NOVO NORDISK A/S , PETTERSSON, Ingrid , SPETZLER, Jane , SCHÄFFER, Lauge , LAU, Jesper , KRUSE, Thomas , GARIBAY, Patrick William , RUNGE, Steffen , THØGERSEN, Henning
发明人： SPETZLER, Jane , SCHÄFFER, Lauge , LAU, Jesper , KRUSE, Thomas , GARIBAY, Patrick William , RUNGE, Steffen , THØGERSEN, Henning
IPC分类号： C07K14/605 , A61K38/26
CPC分类号： C07K14/605 , A61K38/26
摘要： The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
摘要翻译：本发明涉及长效的胰高血糖素样肽-1（GLP-1）衍生物及其治疗用途。本发明的GLP-1衍生物包含具有总共2-12个氨基酸修饰的修饰的GLP-1（7-37）序列，包括Glu22和Arg26，并用白蛋白结合残基衍生或在18位聚乙二醇化， 20,23,30,31,34,36,37或39.这些化合物可用于治疗或预防2型糖尿病和相关疾病。该化合物是有效的，稳定的，具有长的半衰期，与白蛋白结合的高亲和力，和/或与GLP-1受体（GLP-1R）细胞外结构域结合的高亲和力，所有这些都是对于实现长效，稳定和活性的GLP-1衍生物的总体目标的潜在相关性，具有每周一次行政的潜力。

16. 发明申请

WO2008133961A2 IGF-1R BINDING PROTEINS AND ANTAGONISTS 审中-公开
标题翻译： IGF-1R结合蛋白和拮抗剂
公开(公告)号：WO2008133961A2
公开(公告)日：2008-11-06
申请号：PCT/US2008/005316
申请日：2008-04-23
申请人： ANTYRA INC. , NOVO NORDISK A/S , OSTERGAARD, Soren , PILLUTLA, Renuta , FLETCHER, Paul , SCHAFFER, Lauge , MATHIASEN, Ida Heise, Stenfeldt , GOLDSTEIN, Neil, L. , SPETZLER, Jane
发明人： OSTERGAARD, Soren , PILLUTLA, Renuta , FLETCHER, Paul , SCHAFFER, Lauge , MATHIASEN, Ida Heise, Stenfeldt , GOLDSTEIN, Neil, L. , SPETZLER, Jane
IPC分类号： C07K14/72 , A61K38/30
CPC分类号： C07K14/72 , A61K38/00
摘要： The present invention is drawn to new peptides and proteins that bind to human insulin-like growth factor- 1 receptor (HIGF-IR), as well as nucleic acids encoding the same, vectors and cells comprising such nucleic acids, pharmaceutical compositions comprising such compounds, and methods of using any thereof, are provided.
摘要翻译：本发明涉及结合人类胰岛素样生长因子-1受体（HIGF-IR）的新肽和蛋白质，以及编码其的核酸，包含该核酸的载体和细胞，包含这些化合物的药物组合物，及其使用方法。

17. 发明申请

WO2006097536A2 DIMERIC PEPTIDE AGONISTS OF THE GLP-1 RECEPTOR 审中-公开
标题翻译： GLP-1受体的二肽拮抗剂
公开(公告)号：WO2006097536A2
公开(公告)日：2006-09-21
申请号：PCT/EP2006/060854
申请日：2006-03-20
申请人： NOVO NORDISK A/S , CHRISTENSEN, Leif , LAU, Jesper , SPETZLER, Jane , HANSEN, Thomas Kruse
发明人： CHRISTENSEN, Leif , LAU, Jesper , SPETZLER, Jane , HANSEN, Thomas Kruse
IPC分类号： A61K47/48 , C07K14/605 , A61K38/26 , A61P3/10
CPC分类号： C07K14/605 , A61K38/00 , A61K47/60 , A61K47/65 , C07K14/57563
摘要： Dimerization of GLP-1 agonists and therapeutic uses thereof.
摘要翻译： GLP-1激动剂的二聚化及其治疗用途。

18. 发明申请

WO2020201041A2 GLUCOSE SENSITIVE INSULIN DERIVATIVES 审中-公开
公开(公告)号：WO2020201041A2
公开(公告)日：2020-10-08
申请号：PCT/EP2020/058641
申请日：2020-03-27
申请人： NOVO NORDISK A/S
发明人： HOEG-JENSEN, Thomas , BEHRENS, Carsten , CLÓ, Emiliano , MÜNZEL, Martin, Werner, Borchsenius , SAUERBERG, Per , KRUSE, Thomas , SPETZLER, Jane , SENSFUSS, Ulrich , HJØRRINGGAARD, Claudia, Ulrich , THØGERSEN, Henning , BALŠÁNEK, Vojtěch , DROBŇÁKOVÁ, Zuzana , DROŽ, Ladislav , HAVRÁNEK, Miroslav , KOTEK, Vladislav , ŠTENGL, Milan , ŠNAJDR, Ivan , VÁŇOVÁ, Hana
IPC分类号： A61K31/69 , A61K47/54 , A61P3/10
摘要： The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention also relates to novel intermediates. Finally, the invention provides a pharmaceutical composition comprising the insulin derivatives of the invention and the use of such a composition in the treatment or prevention of medical conditions relating to diabetes.

19. 发明申请

WO2019219714A1 COMPOUNDS CAPABLE OF BINDING TO MELANOCORTIN 4 RECEPTOR 审中-公开
公开(公告)号：WO2019219714A1
公开(公告)日：2019-11-21
申请号：PCT/EP2019/062396
申请日：2019-05-15
申请人： NOVO NORDISK A/S
发明人： FRIEBOES, Kilian, Waldemar, Conde , SPETZLER, Jane , TORNØE, Christian, Wenzel , NIELSEN, Line, Marie
IPC分类号： C07K14/68 , A61K38/34 , C07K14/435 , A61K38/12 , C07K7/64
摘要： The present invention relates to novel peptide compounds which are effective as melanocortin 4 receptor agonists, to the use of the compounds in medicine, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds for the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of overweight and obesity as well as a variety of diseases or conditions associated with obesity.

20. 发明申请

WO2016055610A1 STABLE GLP-1 BASED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS 审中-公开
标题翻译：稳定的基于GLP-1的GLP-1 / GLUCAGON受体共同作用
公开(公告)号：WO2016055610A1
公开(公告)日：2016-04-14
申请号：PCT/EP2015/073372
申请日：2015-10-09
申请人： NOVO NORDISK A/S
发明人： REEDTZ-RUNGE, Steffen , SENSFUSS, Ulrich , KRUSE, Thomas , SPETZLER, Jane , THØGERSEN, Henning , WENZEL TORNØE, Christian , LAU, Jesper F.
IPC分类号： C07K14/605 , A61K38/26
CPC分类号： C07K14/605 , A61K38/00
摘要： The application concerns stable and protracted GLP-1 derivatives which are GLP-l/glucagon receptor co-agonists, compositions thereof, use of the GLP-1 derivatives in medicine, and to methods of treatment comprising administration of the GLP-1 derivatives to patients, including treatment of diabetes, obesity and related diseases and conditions. Prefered GLP-1 derivatives comprise a polypeptide consisting of the amino acid sequence of Formula I: lmp-X8-His-Gly-Thr-Phe-Thr-Ser-Asp-Xl 6-Ser-Xi 8-Tyr-Leu-Glu-X22- X23-Ala-Ala -X26-X27-Phe-I le-Ala-Trp-Leu-X33-X34-X35-X36-X37 [I], wherein - X8 is Ala, Aib, Acb, or Gly; - X16 is Val, Leu, lie, or Tyr; - X18 is Lys or Arg; - X22 is Gly, Ala, Glu, Lys, Arg, Ser, orAib; - X23 is Gin, Arg, or Lys; - X26 is Lys or Arg; - X27 is Glu or Lys; - X33 is Val, Leu, or lle; - X34 is Lys or Arg; - X35 is Gly, Thr, Lys, or is absent; - X36 is Ala, Gly, Lys, Ser, or is absent; - X37 is Gly or is absent; wherein said GLP-i derivative further comprises a substituent comprising a lipophilic moiety and at least two negatively charged moieties, wherein one of said negatively charged moieties is distal of a lipophilic moiety; wherein said polypeptide optionally comprises a C-terminal amide; or a pharmaceutically acceptable salt and/or ester thereof.
摘要翻译：本申请涉及GLP-1 /胰高血糖素受体共激动剂，其组合物，GLP-1衍生物在医药中的用途以及包括向患者施用GLP-1衍生物的治疗方法的稳定和延长的GLP-1衍生物，包括治疗糖尿病，肥胖症及相关疾病和病症。优选的GLP-1衍生物包含由式I的氨基酸序列组成的多肽：1mp-X8-His-Gly-Thr-Phe-Thr-Ser-Asp-X116-Ser-Xi 8-Tyr-Leu-Glu- X22-X23-Ala-Ala -X26-X27-Phe-Ile-Ala-Trp-Leu-X33-X34-X35-X36-X37 [I]，其中-X8是Ala，Aib，Acb或Gly; - X16是Val，Leu，lie或Tyr; -X18是Lys或Arg; - X22是Gly，Ala，Glu，Lys，Arg，Ser或Aib; - X23是Gin，Arg或Lys; - X26是Lys或Arg; - X27是Glu或Lys; - X33是Val，Leu或lle; - X34是Lys或Arg; - X35是Gly，Thr，Lys，或不存在; - X36是Ala，Gly，Lys，Ser，或不存在; - X37是Gly或不存在; 其中所述GLP-1衍生物还包含包含亲脂部分和至少两个带负电荷的部分的取代基，其中所述带负电荷的部分之一是亲脂性部分的远端; 其中所述多肽任选地包含C-末端酰胺; 或其药学上可接受的盐和/或酯。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式